Identification of Tumor Suppressive Genes Regulated by miR-31-5p and miR-31-3p in Head and Neck Squamous Cell Carcinoma

Abstract

We identified the microRNA (miRNA) expression signature of head and neck squamous cell carcinoma (HNSCC) tissues by RNA sequencing, in which 168 miRNAs were significantly upregulated, including both strands of the miR-31 duplex (miR-31-5p and miR-31-3p). The aims of this study were to identify networks of tumor suppressor genes regulated by miR-31-5p and miR-31-3p in HNSCC cells. Our functional assays showed that inhibition of miR-31-5p and miR-31-3p attenuated cancer cell malignant phenotypes (cell proliferation, migration, and invasion), suggesting that they had oncogenic potential in HNSCC cells. Our in silico analysis revealed 146 genes regulated by miR-31 in HNSCC cells. Among these targets, the low expression of seven genes (miR-31-5p targets: CACNB2 and IL34; miR-31-3p targets: CGNL1, CNTN3, GAS7, HOPX, and PBX1) was closely associated with poor prognosis in HNSCC. According to multivariate Cox regression analyses, the expression levels of five of those genes (CACNB2: p = 0.0189; IL34: p = 0.0425; CGNL1: p = 0.0014; CNTN3: p = 0.0304; and GAS7: p = 0.0412) were independent prognostic factors in patients with HNSCC. Our miRNA signature and miRNA-based approach will provide new insights into the molecular pathogenesis of HNSCC.

1. Introduction

Head and neck squamous cell carcinoma (HNSCC) arises from the oral cavity, larynx, or pharynx and is ranked the sixth most common cancer [1,2]. In 2018, approximately 84,000 cases of HNSCC were newly diagnosed, and more than 43,000 people died of this disease worldwide [3]. Surgery, radiation therapy, and cisplatin-based chemotherapy are the main treatment strategies for head and neck cancers. At the time of the initial diagnosis, most patients have advanced-stage disease and a poor prognosis (5-year survival rate < 60%) due to lymph node metastasis or recurrence [1]. In addition, cancer cells acquire resistance to cisplatin-based treatment, and the prognosis of patients who fail treatment is extremely poor [4]. The therapeutic effects of molecular-targeted drugs and immune checkpoint inhibitors in patients after treatment failure are poorly understood [5,6].

The Human Genome Project revealed that an extremely large number of non-coding RNAs (ncRNAs) are transcribed from the human genome, and these ncRNAs function in both normal and diseased cells [7,8]. Among ncRNAs, microRNAs (miRNAs) are endogenous single-stranded RNA molecules 19–22 nucleotides long that function as fine tuners of RNA expression in a sequence-dependent manner [9,10]. A unique feature of miRNAs is that a single miRNA negatively regulates a vast number of RNA transcripts (both protein-coding RNAs and ncRNAs) in each cell [10]. Moreover, bioinformatic studies have shown that more than half of protein-coding genes are controlled by miRNAs [11]. Numerous studies have indicated that aberrantly expressed miRNAs disrupt the tightly controlled RNA networks in normal cells, and these events trigger transformation to a disease state [12,13].

Identification of differentially expressed miRNAs in the cancer tissues of interest is the initial step. The latest RNA sequencing technology has successfully resulted in identification of miRNA expression signatures in cancer tissues. Our HNSCC miRNA signature revealed that both strands of the miR-31 duplex (miR-31-5p and miR-31-3p) are upregulated in cancer tissues. Numerous cohort data from The Cancer Genome Atlas (TCGA) confirmed that miR-31-5p and miR-31-3p are upregulated in HNSCC tissues. The aim of this study was to investigate the oncogenic roles of these miRNA strands and to identify their tumor suppressor gene targets in HNSCC cells.

Identification of differentially expressed miRNAs and their regulated molecular networks may be an effective strategy for elucidating the molecular pathogenesis of HNSCC.

2. Results

2.1. Identification of the miRNA Expression Signature of HNSCC by RNA Sequencing

Six cDNA libraries (derived from three HNSCC tissues and three normal oral epithelial tissues) were analyzed by RNA sequencing. After a trimming procedure, 955,347–1,927,436 reads were successfully mapped to the human miRNAs (Table S1). The clinical features of the HNSCC specimens using in this study are summarized in Table S2.

A total of 168 miRNAs were identified as upregulated (log2 fold change > 1.5) in HNSCC tissues (Figure 1A and Table S3).

2.2. Expression Levels and Clinical Significance of miR-31-5p and miR-31-3p in HNSCC

We focused on miRNAs of which both strands (the guide strand and passenger strand) derived from pre-miRNAs were upregulated in this signature. A total of 7 pre-miRNAs (miR-31, miR-223, miR-4655, miR-4781, miR-6753, miR-6830, and miR-6871) were detected in this signature (Figure 1A and Table S3). From TCGA-HNSC database analysis, it was confirmed that miR-31 is the only miRNA whose expression of both strands were significantly upregulated in HNSCC tissues among 7 pre-miRNAs (Figure 1B). The expression of neither miRNA was associated with worse overall survival rates in patients with HNSCC according to analysis of TCGA-HNSC data (Figure 1C).

In this study, we focused on miR-31-5p and miR-31-3p, and continued to investigate the functional aspects of these miRNAs.

2.3. Effects of Inhibition of miR-31-5p and miR-31-3p Expression on the Proliferation, Migration, and Invasion of HNSCC Cells

First, we measured the expression levels of miR-31-5p and miR-31-3p in 11 HNSCC cell lines compared with fibroblast cell lines (IMR-90 and MRC-5). Detailed information on the cell lines used is shown in the Table S4. Overexpression of miR-31-5p and miR-31-3p was detected in several HNSCC cell lines, e.g., Ca9-22, HSC-2, HSC-4, and SAS (Figure S1), relative to fibroblasts. We selected two of these HNSCC cell lines, SAS and HSC-2, to investigate the oncogenic roles of these miRNAs. To suppress the expression of miR-31-5p and miR-31-3p, we used inhibitors (Anti-miR^TM miRNA Inhibitor) of these miRNAs. The inhibitors were used at a concentration of 30 nM. To evaluate their effects in functional assays, we confirmed the expression of miR-31-5p and miR-31-3p after transfection of inhibitors into SAS and HSC-2 cells (Figure S2). Inhibition of miR-31-5p and miR-31-3p attenuated the proliferation (Figure 2A and Figure S3) and markedly decreased the migration and invasion (Figure 2B,C and Figure S4) of SAS and HSC-2 cells. These data suggest that upregulation of miR-31-5p and miR-31-3p has an oncogenic effect in HNSCC cells.

2.4. Screening of miR-31-5p and miR-31-3p Targets in HNSCC Cells

Based on our hypothesis that miR-31-5p and miR-31-3p regulate tumor suppressor genes in HNSCC cells, we screened miR-31-5p and miR-31-3p target genes using in silico analyses and our gene expression data (GEO accession no. GSE172120). Our strategy for identifying miR-31-5p/miR-31-3p gene targets is shown in Figure 3.

Analysis of the TargetScan database revealed that 477 genes and 2387 genes had putative miR-31-5p and miR-31-3p binding sites, respectively, within their 3′-UTR [14]. Next, we compared these genes with those downregulated in HNSCC clinical tissues, and 146 genes were shared between the data sets (24 and 122 genes were miR-31-5p and miR-31-3p targets, respectively and they are summarized in

Table 1. A. Candidate target genes regulated by miR-31-5p. B. Candidate target genes regulated by miR-31-3p.

A
Entrez Gene ID	Gene Symbol	Gene Name	Fold Change (log2 < −2.0)	Total Sites
5563	PRKAA2	protein kinase, AMP-activated, alpha 2 catalytic subunit	−4.56	1
83699	SH3BGRL2	SH3 domain binding glutamate-rich protein like 2	−4.45	1
6517	SLC2A4	solute carrier family 2 (facilitated glucose transporter), member 4	−4.29	1
2252	FGF7	fibroblast growth factor 7	−3.81	1
55607	PPP1R9A	protein phosphatase 1, regulatory subunit 9A	−3.73	1
5549	PRELP	proline/arginine-rich end leucine-rich repeat protein	−3.66	2
5083	PAX9	paired box 9	−3.62	1
26084	ARHGEF26	Rho guanine nucleotide exchange factor (GEF) 26	−3.58	1
252995	FNDC5	fibronectin type III domain containing 5	−3.50	1
51209	RAB9B	RAB9B, member RAS oncogene family	−3.23	1
2899	GRIK3	glutamate receptor, ionotropic, kainate 3	−2.88	1
401474	SAMD12	sterile alpha motif domain containing 12	−2.84	1
60529	ALX4	ALX homeobox 4	−2.63	1
64399	HHIP	hedgehog interacting protein	−2.53	1
146433	IL34	interleukin 34	−2.45	1
84144	SYDE2	synapse defective 1, Rho GTPase, homolog 2 (C. elegans)	−2.44	2
619279	ZNF704	zinc finger protein 704	−2.40	1
783	CACNB2	calcium channel, voltage-dependent, beta 2 subunit	−2.34	1
5493	PPL	periplakin	−2.27	1
3670	ISL1	ISL LIM homeobox 1	−2.24	2
389208	TMPRSS11F	transmembrane protease, serine 11F	−2.17	1
168667	BMPER	BMP binding endothelial regulator	−2.16	1
1983	EIF5	eukaryotic translation initiation factor 5	−2.14	1
5100	PCDH8	protocadherin 8	−2.06	2
B
Entrez Gene ID	Gene Symbol	Gene Name	Fold Change (log2 < −2.0)	Total Sites
420	ART4	ADP-ribosyltransferase 4 (Dombrock blood group)	−6.92	1
5075	PAX1	paired box 1	−6.47	1
1805	DPT	dermatopontin	−5.69	1
10218	ANGPTL7	angiopoietin-like 7	−5.09	1
2315	MLANA	melan-A	−4.81	1
55286	C4orf19	chromosome 4 open reading frame 19	−4.76	1
8839	WISP2	WNT1 inducible signaling pathway protein 2	−4.72	1
440854	CAPN14	calpain 14	−4.70	1
6422	SFRP1	secreted frizzled-related protein 1	−4.70	1
114905	C1QTNF7	C1q and tumor necrosis factor related protein 7	−4.66	1
9068	ANGPTL1	angiopoietin-like 1	−4.56	1
5563	PRKAA2	protein kinase, AMP-activated, alpha 2 catalytic subunit	−4.56	2
5104	SERPINA5	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5	−4.45	1
148213	ZNF681	zinc finger protein 681	−4.27	1
127435	PODN	podocan	−4.20	1
53405	CLIC5	chloride intracellular channel 5	−4.16	1
85477	SCIN	scinderin	−4.09	1
255798	SMCO1/C3orf43	single-pass membrane protein with coiled-coil domains 1	−4.01	1
53353	LRP1B	low density lipoprotein receptor-related protein 1B	−4.00	1
23242	COBL	cordon-bleu WH2 repeat protein	−3.89	1
5570	PKIB	protein kinase (cAMP-dependent, catalytic) inhibitor beta	−3.84	1
440730	TRIM67	tripartite motif containing 67	−3.83	1
2252	FGF7	fibroblast growth factor 7	−3.81	1
84525	HOPX	HOP homeobox	−3.81	1
389432	SAMD5	sterile alpha motif domain containing 5	−3.79	1
8736	MYOM1	myomesin 1	−3.68	1
5549	PRELP	proline/arginine-rich end leucine-rich repeat protein	−3.66	2
137735	ABRA	actin-binding Rho activating protein	−3.58	1
785	CACNB4	calcium channel, voltage-dependent, beta 4 subunit	−3.57	3
79442	LRRC2	leucine rich repeat containing 2	−3.55	2
339512	C1orf110	chromosome 1 open reading frame 110	−3.50	1
10894	LYVE1	lymphatic vessel endothelial hyaluronan receptor 1	−3.43	1
3768	KCNJ12	potassium channel, inwardly rectifying subfamily J, member 12	−3.36	1
171024	SYNPO2	synaptopodin 2	−3.35	1
114786	XKR4	XK, Kell blood group complex subunit-related family, member 4	−3.33	1
84952	CGNL1	cingulin-like 1	−3.30	2
55335	NIPSNAP3B	nipsnap homolog 3B (C. elegans)	−3.27	1
3479	IGF1	insulin-like growth factor 1 (somatomedin C)	−3.26	2
2690	GHR	growth hormone receptor	−3.20	1
8522	GAS7	growth arrest-specific 7	−3.18	1
2066	ERBB4	erb-b2 receptor tyrosine kinase 4	−3.14	2
202333	CMYA5	cardiomyopathy associated 5	−3.13	1
22865	SLITRK3	SLIT and NTRK-like family, member 3	−3.13	1
51666	ASB4	ankyrin repeat and SOCS box containing 4	−3.08	1
22871	NLGN1	neuroligin 1	−3.08	1
4958	OMD	osteomodulin	−3.08	1
5178	PEG3	paternally expressed 3	−3.06	1
29119	CTNNA3	catenin (cadherin-associated protein), alpha 3	−3.04	2
8529	CYP4F2	cytochrome P450, family 4, subfamily F, polypeptide 2	−3.01	1
343450	KCNT2	potassium channel, sodium activated subfamily T, member 2	−3.00	1
5087	PBX1	pre-B-cell leukemia homeobox 1	−2.98	1
387758	FIBIN	fin bud initiation factor homolog (zebrafish)	−2.96	1
57689	LRRC4C	leucine rich repeat containing 4C	−2.96	1
79071	ELOVL6	ELOVL fatty acid elongase 6	−2.95	1
6542	SLC7A2	solute carrier family 7 (cationic amino acid transporter, y+ system), member 2	−2.94	1
6450	SH3BGR	SH3 domain binding glutamate-rich protein	−2.93	1
7276	TTR	transthyretin	−2.92	2
23732	FRRS1L/C9orf4	ferric-chelate reductase 1-like	−2.89	1
220963	SLC16A9	solute carrier family 16, member 9	−2.88	1
55	ACPP	acid phosphatase, prostate	−2.84	1
401474	SAMD12	sterile alpha motif domain containing 12	−2.84	1
8153	RND2	Rho family GTPase 2	−2.83	1
7135	TNNI1	troponin I type 1 (skeletal, slow)	−2.82	1
340596	LHFPL1	lipoma HMGIC fusion partner-like 1	−2.77	1
26974	ZNF285	zinc finger protein 285	−2.74	1
2053	EPHX2	epoxide hydrolase 2, cytoplasmic	−2.73	1
386618	KCTD4	potassium channel tetramerization domain containing 4	−2.73	1
1183	CLCN4	chloride channel, voltage-sensitive 4	−2.69	1
291	SLC25A4	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4	−2.68	1
4023	LPL	lipoprotein lipase	−2.65	1
32	ACACB	acetyl-CoA carboxylase beta	−2.64	1
55244	SLC47A1	solute carrier family 47 (multidrug and toxin extrusion), member 1	−2.64	1
84620	ST6GAL2	ST6 beta-galactosamide alpha-2,6-sialyltranferase 2	−2.62	1
26032	SUSD5	sushi domain containing 5	−2.61	1
6857	SYT1	synaptotagmin I	−2.61	2
6391	SDHC	succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa	−2.60	1
5506	PPP1R3A	protein phosphatase 1, regulatory subunit 3A	−2.58	2
367	AR	androgen receptor	−2.57	2
64399	HHIP	hedgehog interacting protein	−2.53	1
56898	BDH2	3-hydroxybutyrate dehydrogenase, type 2	−2.52	2
9077	DIRAS3	DIRAS family, GTP-binding RAS-like 3	−2.52	1
154661	RUNDC3B	RUN domain containing 3B	−2.52	1
8796	SCEL	sciellin	−2.52	1
50937	CDON	cell adhesion associated, oncogene regulated	−2.49	1
6660	SOX5	SRY (sex determining region Y)-box 5	−2.48	1
56172	ANKH	ANKH inorganic pyrophosphate transport regulator	−2.46	1
6092	ROBO2	roundabout, axon guidance receptor, homolog 2 (Drosophila)	−2.46	1
158326	FREM1	FRAS1 related extracellular matrix 1	−2.45	1
10345	TRDN	triadin	−2.45	1
158866	ZDHHC15	zinc finger, DHHC-type containing 15	−2.44	1
55283	MCOLN3	mucolipin 3	−2.42	1
653316	FAM153C	family with sequence similarity 153, member C, pseudogene	−2.41	1
348158	ACSM2B	acyl-CoA synthetase medium-chain family member 2B	−2.39	1
11227	GALNT5	polypeptide N-acetylgalactosaminyltransferase 5	−2.39	1
3169	FOXA1	forkhead box A1	−2.37	1
284716	RIMKLA	ribosomal modification protein rimK-like family member A	−2.37	2
253559	CADM2	cell adhesion molecule 2	−2.36	1
144453	BEST3	bestrophin 3	−2.35	1
2258	FGF13	fibroblast growth factor 13	−2.35	1
57863	CADM3	cell adhesion molecule 3	−2.34	1
140456	ASB11	ankyrin repeat and SOCS box containing 11, E3 ubiquitin protein ligase	−2.32	2
346389	MACC1	metastasis associated in colon cancer 1	−2.30	2
9378	NRXN1	neurexin 1	−2.30	1
151887	CCDC80	coiled-coil domain containing 80	−2.29	2
266977	GPR110	G protein-coupled receptor 110	−2.28	1
3481	IGF2	insulin-like growth factor 2	−2.27	1
57554	LRRC7	leucine rich repeat containing 7	−2.27	1
80310	PDGFD	platelet derived growth factor D	−2.25	1
342926	ZNF677	zinc finger protein 677	−2.25	1
341640	FREM2	FRAS1 related extracellular matrix protein 2	−2.24	1
5067	CNTN3	contactin 3 (plasmacytoma associated)	−2.22	1
4919	ROR1	receptor tyrosine kinase-like orphan receptor 1	−2.20	1
948	CD36	CD36 molecule (thrombospondin receptor)	−2.19	1
23171	GPD1L	glycerol-3-phosphate dehydrogenase 1-like	−2.18	1
64102	TNMD	tenomodulin	−2.18	2
55638	SYBU	syntabulin (syntaxin-interacting)	−2.17	1
6586	SLIT3	slit homolog 3 (Drosophila)	−2.13	2
2247	FGF2	fibroblast growth factor 2 (basic)	−2.11	1
115827	RAB3C	RAB3C, member RAS oncogene family	−2.11	2
203859	ANO5	anoctamin 5	−2.10	1
80110	ZNF614	zinc finger protein 614	−2.10	1
115265	DDIT4L	DNA-damage-inducible transcript 4-like	−2.03	1

). Furthermore, we performed a clinicopathological analysis of these candidate genes using data from TCGA-HNSC. Seven genes (CACNB2, IL34, CGNL1, CNTN3, GAS7, HOPX, and PBX1) regulated by miR-31-5p and miR-31-3p were identified as putative tumor suppressors. Of these genes, five (CACNB2, IL34, CGNL1, CNTN3, and GAS7) were identified as independent prognostic factors by multivariate analysis.

2.5. Clinical Significance of miR-31-5p and miR-31-3p Targets in HNSCC Cells

Among the 146 miR-31-5p and miR-31-3p gene targets, the low expression of seven (CACNB2: p = 0.0018; IL34: p = 0.0031; CGNL1: p = 0.0012; CNTN3: p = 0.0061; GAS7: p = 0.0093; HOPX: p = 0.0345; and PBX1: p = 0.0247) significantly predicted a worse prognosis in patients with HNSCC by Kaplan–Meier analysis (Figure 4 and Figure 5). Notably, multivariate Cox regression analyses revealed that the expression levels of five of those genes (CACNB2: p = 0.0189; IL34: p = 0.0425; CGNL1: p = 0.0014; CNTN3: p = 0.0304; and GAS7: p = 0.0412) were independent prognostic factors in patients with HNSCC (Figure 6). Moreover, expression negative correlation between miR-31 and their target genes were investigated by TCGA-HNSC database (Figure 7).

2.6. Direct Regulation of CGNL1 by miR-31-3p in HNSCC Cells

We focused on CGNL1, which has the most significant difference in clinical statistics, from among the five target genes of miR-31-5p and miR-31-3p, and verified the direct regulation of CGNL1 by miR-31-3p. In cells transfected with miR-31-3p, the levels of CGNL1 mRNA and CGNL1 protein were significantly lower than in mock- or miR-control-transfected cells (Figure 8A,B).

We performed dual-luciferase reporter assays to determine whether CGNL1 was directly regulated by miR-31-3p. We used vectors encoding the partial wild-type sequences of the 3′-UTR of CGNL1 and vector with partially deleted CGNL1 3′-UTR (Figure 8C). We found that luciferase activity was significantly decreased by cotransfection with miR-31-3p and the vector carrying the wild-type 3′-UTR of CGNL1, whereas transfection with the deletion vector blocked the decrease in luminescence in SAS cells (Figure 8D). These data showed that miR-31-3p directly bound to CGNL1.

3. Discussion

The latest RNA-sequencing technologies have enabled identification of genome-wide miRNA expression signatures in human cancers. Our recent studies of miRNA signatures revealed that the passenger strands of some miRNA duplexes, such as miR-99a-3p, miR-145-3p, miR-150-3p and miR-199a-3p, act as tumor suppressors by directly targeting several oncogenes in HNSCC cells [15,16,17,18]. The original theory regarding miRNA biogenesis is that the guide strand of the miRNA duplex is incorporated into the RNA-induced silencing complex and functions as a negative regulator of gene expression, whereas the passenger strand is degraded in the cytoplasm and nonfunctional [10,11]. However, numerous in silico studies (involving over 5200 patients with 14 types of cancers) have shown that both strands (5p and 3p) of some miRNA duplexes (e.g., miR-30a, miR-139, miR-143, and miR-145) function together to regulate pivotal targets and pathways in several types of cancers [19]. Studies on the passenger strands of miRNAs will reveal novel molecular mechanisms of cancer pathogenesis.

In this study, we focused on miR-31-5p and miR-31-3p based on our miRNA signatures. Upregulation of miR-31-5p and miR-31-3p in HNSCC tissues was confirmed by TCGA data analysis. Our functional assays indicated that these miRNAs act as oncogenic miRNAs in HNSCC cells. Previous studies demonstrated that miR-31 has opposing roles (oncogene vs. tumor suppressor) depending on the type of cancer [20].

In esophageal squamous cell carcinoma, miR-31 was upregulated in clinical specimens and acted as an oncogenic miRNA by targeting the tumor suppressor gene LATS2, which is involved in the Hippo pathway [21]. Upregulation of miR-31 was reported in HNSCC tissues, and its expression activated the hypoxia-inducible factor pathway by targeting factor-inhibiting hypoxia-inducible factor [22,23]. Signaling via epidermal growth factor and its receptor is an essential oncogenic pathway in HNSCC and oral squamous cell carcinoma (OSCC), and this signaling pathway enhanced AKT activation and upregulated C/EBPβ expression in OSCC [24]. These events induced upregulation of miR-31 in OSCC cells [24]. Interestingly, a previous study showed that exogenous expression of miR-31 and telomerase reverse transcriptase transformed normal oral keratinocytes into immortalized cells [25]. Those previous and our present results indicate that upregulation of miR-31 downregulates genes/pathways intricately involved in malignant transformation of HNSCC and OSCC.

Our other aim was to clarify the novel molecular pathways regulated by miR-31-5p and miR-31-3p in HNSCC cells. Our in silico analysis revealed that five genes (CACNB2, IL34, CGNL1, CNTN3, and GAS7) are closely associated with HNSCC molecular pathogenesis. Functional analyses of these genes are needed to reveal the molecular mechanisms of HNSCC malignant phenotypes.

Of the five genes, GAS7 was initially cloned from serum-starved mouse NIH3T3 cells, and it consists of a series of different functional domains from the N- to C-termini: Src homology 3 domain, WW domain, and FES-CIP4 homology domain [26]. GAS7 regulates the dynamic activities of the membrane, actin cytoskeleton, and microtubules [26,27]. Downregulation of GAS7 has been reported in several cancer types, and ectopic expression of GAS7 inhibited the migration of lung and breast cancer cells [28]. More recently, it was reported that loss of GAS7 expression accelerated metastasis of neuroblastoma harboring MYCN overexpression or amplification [29]. Previous studies indicated that GAS7 acts as a tumor suppressor in human cancers.

Analysis of TCGA data showed that IL34 is downregulated in HNSCC tissues, and its low expression significantly predicts a poor prognosis in patients with HNSCC. IL34 stimulates the differentiation of monocytes into macrophages via the CSF-1 receptor [30]. IL34 is also a ligand of the macrophage colony stimulating factor receptor [31]. Recent studies showed that IL34 is expressed in various types of cancers and is involved in cancer progression and metastasis [32]. In the future, it is necessary to investigate the functional significance of IL34 in HNSCC.

CGNL1 is a paralogue of cingulin, which is ubiquitously expressed in endothelial cells and localized at tight junctions [33,34]. A previous study showed that cingulin binds to actin filament bundles to bridge tight junctions and actin filaments [35]. CGNL1 is localized on actin filament bundles and has multiple roles depending on its binding partner [35]. Previous reports showed that CGNL1 is an inhibitor of RhoA activity in tight junctions but is also involved in Rac1 activation in Madin–Darby canine kidney epithelial cells [36,37]. CGNL1 likely has various functions by interacting with different types of GEFs and GAPs in each cell. Few detailed functional analyses of CGNL1 have been performed in cancer cells. Expression of CGNL1 was downregulated in HNSCC tissues compared with normal epithelial tissues in numerous TCGA datasets. GEPIA2 database (http://gepia2.cancer-pku.cn/#index, accessed on 20 April 2021) analyses showed that expression of CGNL1 was significantly downregulated in cervical squamous cell carcinoma, esophageal carcinoma, and lung squamous cell carcinoma, suggesting that CGNL1 is downregulated in human squamous cell carcinoma. These findings suggest that CGNL1 plays a tumor suppressor role in HNSCC cells [38]. Sufficient functional analysis of CGNL1 in HNSCC remains unresolved in this study. By clarifying the tumor suppressive function of this gene in the future, a part of the molecular mechanism of HNSCC will be clarified.

We newly created the miRNA expression signature of HNSCC by RNA sequencing. Analysis of the signature revealed that both strands of pre-miR-31 (the guide strand of miR-31-5p and the passenger strand of miR-31-3p) acted as oncogenic miRNAs in HNSCC cells. Our in silico analysis showed that a total of 5 genes (CACNB2, IL34, CGNL1, CNTN3, and GAS7) were independent prognostic factors in patients with HNSCC. Our HNSCC miRNA signature and miRNA-based analyses will provide important insights into the molecular pathogenesis of HNSCC.

4. Materials and Methods

4.1. Clinical HNSCC and Normal Epithelial Tissue Specimens and HNSCC Cell Lines

Six specimens (three HNSCC tissues and three normal oral epithelial tissues) were analyzed by RNA sequencing to determine the HNSCC miRNA signature. The clinical features of HNSCC patients are summarized in Table S2.

All specimens used were obtained by surgical resection at Chiba University Hospital. All patients provided written informed consent for the use of their specimens. This study was approved by the Bioethics Committee of Chiba University (approval number: 28–65, 10 February 2015).

Two human HNSCC cell lines (HSC-2 and SAS) were obtained from the RIKEN BioResource Center (Tsukuba, Ibaraki, Japan) and used in this study.

4.2. Determination of the miRNA Expression Signature in HNSCC by RNA Sequencing

Small RNAs were sequenced to determine the miRNA expression signature of HNSCC. The RNA sequencing procedure was described in our previous studies [39,40,41,42].

4.3. RNA Extraction and Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR)

RNA was extracted from clinical specimens and cell lines [15,16,17,18] and subjected to qRT-PCR for miRNA expression analysis [15,16,17,18] as described previously. The TaqMan probes, primers used in this study are listed in Table S5.

4.4. Transfection of Mirnas Precursors and Inhibitors into HNSCC Cells

The procedures used for transfection of miRNA precursors and inhibitors into HNSCC cells have been described previously [15,16,17,18]. The reagents used in this study are listed in Table S5.

4.5. Functional Assays (Cell Proliferation, Migration, and Invasion) in HNSCC Cells

The procedures used for the functional assays in cancer cells (proliferation, migration, and invasion) have been described in our previous studies [15,16,17,18]. Cells were transfected with 30 nM miRNA inhibitors. Cell proliferation was evaluated by XTT assay. Migration assays were performed using uncoated transwell polycarbonate membrane filters, and invasion assays were conducted using modified Boyden chambers.

4.6. Analysis of the Clinical Significance of HNSCC Patients Using TCGA-HNSC Data

The strategy used to identify miRNA target genes is presented in Figure 3. We selected putative target genes with miR-31-5p and miR-31-3p binding sites using TargetScanHuman ver. 7.2 (http://www.targetscan.org/vert_72/; data were downloaded on 10 July 2020). The expression profiles of HNSCC clinical specimens (genes downregulated in HNSCC tissues) were used for screening miRNA target genes [14]. Our expression data were deposited in the GEO database (accession number: GSE172120). Furthermore, we narrowed down the candidate genes by factoring in clinical information from TCGA-HNSC analyses.

For the Kaplan–Meier survival analysis, we downloaded TCGA-HNSC clinical data (TCGA, Firehose Legacy) from cBioportal (https://www.cbioportal.org, accessed on 10 April 2020). Gene expression data for each gene were collected from OncoLnc (http://www.oncolnc.org, accessed on 20 April 2021) [43]. For the log-rank test, we used R ver. 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria), and “survival” and “survminer” packages.

Multivariate Cox regression analyses were also performed using TCGA-HNSC clinical data and survival data according to the expression level of each gene from OncoLnc to identify factors associated with HNSCC patient survival [43]. In addition to gene expression, the tumor stage, pathological grade, and age were evaluated as potential independent prognostic factors. The multivariate analyses were performed using JMP Pro 15.0.0 (SAS Institute Inc., Cary, NC, USA).

4.7. Western Blotting

Cell lysates were prepared 48 h after transfection with RIPA buffer (Nacalai Tesque, Chukyo-ku, Kyoto, Japan). Then, 20 μg of protein lysates were separated on 4–12% Bis-Tris gel and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA, USA) and blocked for 1 h at room temperature with Blocking One (Nacalai Tesque, Inc., Kyoto, Japan). The antibodies used in this study are shown in Table S5.

4.8. Plasmid Construction and Dual-Luciferase Reporter Assays

The partial wild-type sequence of the CGNL1 3′-untranslated region (3′-UTR) was inserted between the XhoI-PmeI restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). Alternatively, we used sequences that were missing the miR-31-3p target sites. The synthesized DNA was cloned into the psiCHECK-2 vector. SAS cells were transfected with 50 ng of the vector, 10 nM microRNAs, and 0.5 µL Lipofectamine 2000 in 50 µL Opti-MEM (both from Invitrogen, Carlsbad, CA, USA).

4.9. Statistical Analysis

Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) and JMP Pro 15 (SAS Institute Inc., Cary, NC, USA). Dunnet’s test were used for multiple group comparisons. For correlation analyses, Spearman’s test was applied. A p value less than 0.05 was considered statistically significant. Bar graphs (Figure 2, Figure 8A,D, Figure S1 and Figure S2) showed mean value and standard error.

5. Conclusions

In this study, we focused on miR-31-5p and miR-31-3p based on our miRNA signatures. Our functional assays indicated that these miRNAs play an oncogenic role in HNSCC cells. Using in silico database analysis to identify gene targets regulated by miR-31-5p and miR-31-3p, we rapidly identified candidate tumor suppressor genes in HNSCC. Our HNSCC miRNA signature and miRNA-based analyses will provide important insights into the molecular pathogenesis of HNSCC.